Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr

US FDA approval is in line with de-risking strategy for additional API site to service our global customer base

Surging demand for Korean pharma in 2023 ahead of CPHI Korea

Pharma in Korea receives a 7% increase in ‘growth potential’ category according to the CPHI Annual Survey findings

New products and nutraceuticals added under Jan Aushadhi Pariyojana

The product basket increased to 1800 medicines and 285 Surgical Equipment

ABDM supports the integration of digital health infrastructure

Health-tech startups have the potential to revolutionize the healthcare sector by supporting innovations

Kintor Pharma completes first patient enrollment in long-term safety phase III trial of KX-826

The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023

PrecisionLife identifies first detailed genetic risk factors for long COVID

Long COVID is a debilitating chronic condition that has affected over 100 million people globally

Venus Remedies gets marketing approvals for oncology medicine from 4 key markets

With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503

Merck to expand reagent production capacity in China

The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons

Industry needs to establish a self-regulatory body to maintain the quality of the pharma products, says Dr Mandaviya

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth